Development ofnivolumab/ipilimumab-associated autoimmune nephritis during steroid therapy

Abstract: Immunotherapy using immune checkpoint inhibitors revolutionized therapies for a variety of malignancies. Nivolumab, an antibody blocking programmed cell death 1 protein, and ipilimumab that blocks cytotoxic T-lymphocyte-associated protein 4 effectively target tumor cells by disinhibiting the endogenous immune response. At the same time, unrestrained T-cell activation may trigger a range of immune-mediated side effects including kidney injury. Steroid therapy constitutes the mainstay of treatment of these adverse events, but dosage, route of administration, and approach to nivolumab re-exposure remain unclear. Here, we report the case of a 72-year-old male patient who developed severe nivolumab/ipilimumab-associated acute kidney injury while on oral steroid therapy for immune-mediated colitis. Acute interstitial nephritis was confirmed by renal biopsy. Administration of high-dose intravenous steroid doses was required to revert declining renal function

Show object

• Location: Deutsche Nationalbibliothek Frankfurt am Main
• Extent: Online-Ressource
• Language: Englisch
• Notes: Case reports in nephrology and dialysis. - 11, 3 (2021) , 270-274, ISSN: 2296-9705

Contributors, Places and Time

• Event: Veröffentlichung
• (where): Freiburg
• (who): Universität
• (when): 2021
• Creator: Gebauer, Ellen ; Bechtel-Walz, Wibke ; Schell, Christoph ; Erbel, Michelle ; Walz, Gerd ; Hermle, Tobias Franz

Further information

• DOI: 10.1159/000517502
• URN: urn:nbn:de:bsz:25-freidok-2225099
• Rights: Kein Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.